Recent Updates
Recently added Catalysts
IMVT Positive Sentiment Score: 70/100

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

Monday, October 27, 2025 1 min read
Key Takeaway: Immunovant (Nasdaq: IMVT) announced it will report its financial results for the second quarter ended September 30, 2025, on November 10, 2025, at 8:00 a.m. ET. The company will also provide a business update during this call. Information regarding the conference call can be found on Immunovant’s investor website, where the archived webcast will be accessible post-call. Immunovant focuses on targeted therapies for individuals with autoimmune diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Immunovant is advancing in its financial reporting and updates.
  • The company is dedicated to developing innovative therapies for autoimmune diseases.
  • As a clinical-stage company, Immunovant is a pioneer in anti-FcRn technology.

Full Press Release Details

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025.
To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
keyur.parekh@roivant.com
stephanie.lee@roivant.com

Frequently Asked Questions

When will Immunovant announce its financial results?

Immunovant will report its financial results on November 10, 2025.

How can I access Immunovant's conference call?

You can register online via the provided registration link to access the call.

Where can I find the archived webcast of the conference?

The archived webcast will be available on Immunovant's website post-conference.

What is Immunovant's focus as a company?

Immunovant specializes in developing therapies for autoimmune diseases.

What technology is Immunovant known for?

Immunovant is a leader in anti-FcRn technology for treating autoimmune conditions.

Tags: IMVT Viatris Investor Conferences Healthcare Immunovant autoimmune diseases clinical-stage financial results anti-FcRn
Last updated: Oct 27, 2025